Simulations Plus provides modeling & simulation software and consulting services from discovery through clinical development, with special emphasis on the QSAR-PBPK “marriage” of GastroPlus® & ADMET Predictor®.

The combination of the industry’s leading PBPK modeling & simulation platform, with the #1-ranked QSAR models, provides an unprecedented ability to screen drugs and chemicals, administered through oral, inhalation, dermal, or IV routes, using virtual animal & human models.

Check out our webinar series to learn how your peers are applying our technology.

• ADMET Predictor provides scientists with an unprecedented capability to data mine compound libraries, quickly design new molecules, generate metabolites, and see how changes in structures affect over 140 ADME-Tox properties.
• Many of these property models feed into GastroPlus, which sets the standard for PBPK/PD modeling for oral (immediate and controlled release formulations), intravenous, inhalation, dermal, and intraoral delivery in human (infants/pediatrics/adults) and animals. Use the program to track plasma or tissue concentrations for parent compounds and any number of metabolites, and easily explore any DDI risks through co-administration of other compounds.
• Two additional products, DDDPlus™ and MembranePlus™ offer mechanistic simulations focused on in vitro dissolution & permeability experiments, respectively, helping you leverage the in vitro-in vivo extrapolation (IVIVE) required for dissolution and absorption modeling.
KIWI™ was created as a cloud-based, validated platform to efficiently and consistently organize, process, and communicate pharmacometric results and the story in front of the pharmacometric analyses.
•And our newest application, PKPlus™, rapidly generates validated NCA/compartmental PK modeling reports for internal research and/or regulatory submissions.

These programs are complemented by our physiologically-based pharmacokinetics (PBPK) and pharmacometric modeling and simulation services and clinical pharmacology support, including model-based drug development strategies, and data assembly.